BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

  • Jefferies Global Healthcare Conference in New York on Wednesday, June 4, 2025, at 4:55 p.m. ET.



  • Goldman Sachs 46th Annual Global Healthcare Conference in Miami on Monday, June 9, 2025, at 8:40 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .

BCRXW

Contact:

John Bluth





EN
27/05/2025

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA Nat...

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. “For more than a decade, we have been...

18h / 49m 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corp...

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. “Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these...

July 7, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual ...

July 3, 2025 1 EN
Wedbush Research
  • Wedbush Research
TSLA TESLA INC
MNKD MANNKIND CORP.
GOOGL ALPHABET INC. CLASS A
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
PTGX PROTAGONIST THERAPEUTICS
ZG ZILLOW GROUP INC. CLASS A
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
COGT COGENT BIOSCIENCES INC
RKT ROCKET COMPANIES
APGE APOGEE THERAPEUTICS INC
06/30/25 June 30, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
BCRX BIOCRYST PHARMACEUTICALS INC.
06/30/25 June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch